BMY, BMYMP, CELG-RI · CIK 0000014272 · operating
Bristol-Myers Squibb discovers, develops, manufactures, and commercializes biopharmaceutical products across multiple therapeutic areas. The company's primary portfolio spans oncology, hematology, immunology, cardiovascular, and neuroscience, with marketed drugs including Opdivo (PD-1 inhibitor for multiple cancer types), Eliquis (anticoagulant for atrial fibrillation and venous thromboembolism), Revlimid (immunomodulatory agent for multiple myeloma), and Orencia (for rheumatoid and psoriatic arthritis). Recent product launches include Cobenfy for schizophrenia, Krazati for KRASG12C-mutated lung cancer, and Sotyktu for plaque psoriasis.
The company operates primarily through the development and marketing of proprietary therapeutics, with revenue derived from both specialty and general pharmaceutical distribution channels, including wholesalers, distributors, specialty pharmacies, hospitals, and government agencies. Bristol-Myers Squibb maintains a global commercial infrastructure supporting worldwide distribution of its branded pharmaceutical products.
As of the latest reporting, the company operates with approximately 32,500 full-time employees and maintains headquarters in Princeton, New Jersey. The company was founded in 1887 and is incorporated in Delaware.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $3.46 | $3.47 | +178.5% | |
| 2024 | $-4.41 | $-4.41 | -214.2% | |
| 2023 | $3.86 | $3.88 | +30.8% | |
| 2022 | $2.95 | $2.97 | -5.4% | |
| 2021 | $3.12 | $3.15 | +170.1% | |
| 2020 | $-4.45 | $-4.45 | -709.1% | |
| 2019 | $-0.55 | $-0.55 | -177.5% | |
| 2018 | $0.71 | $0.71 | +150.0% | |
| 2017 | $-1.42 | $-1.42 | -367.9% | |
| 2016 | $0.53 | $0.53 | +541.7% | |
| 2015 | $-0.12 | $-0.12 | -1300.0% | |
| 2014 | $0.01 | $0.01 | -97.7% | |
| 2013 | $0.44 | $0.44 | -21.4% | |
| 2012 | $0.56 | $0.56 | +12.0% | |
| 2011 | $0.50 | $0.50 | +78.6% | |
| 2010 | $0.28 | $0.28 | -94.8% | |
| 2009 | $5.34 | $5.35 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-11 | 0000014272-26-000004 | SEC ↗ |
| 2024-12-31 | 2025-02-12 | 0000014272-25-000039 | SEC ↗ |
| 2023-12-31 | 2024-02-13 | 0000014272-24-000044 | SEC ↗ |
| 2022-12-31 | 2023-02-14 | 0000014272-23-000046 | SEC ↗ |
| 2021-12-31 | 2022-02-09 | 0000014272-22-000051 | SEC ↗ |
| 2020-12-31 | 2021-02-10 | 0000014272-21-000066 | SEC ↗ |
| 2019-12-31 | 2020-02-24 | 0000014272-20-000082 | SEC ↗ |
| 2018-12-31 | 2019-02-25 | 0000014272-19-000047 | SEC ↗ |